Download now: How To Invest in the Coming Bitcoin Boom

The Tiny Company That Could Cure Cancer

The Biggest Medical Breakthrough Since Antibiotics

Written by Jason Williams
Posted January 1, 2018

First, happy New Year! As we leave 2017 behind and put our best foot forward into 2018, I’ve been taking some time to think about the deeper things in life.

I’ve been stressed out for the past couple of weeks trying to get everything taken care of for the holidays... packing for trips, cleaning for guests, home improvement projects I (like a genius) started in December, buying gifts, wrapping said gifts, writing articles for Wealth Daily, and making sure to keep the readers of my investing service, The Wealth Advisory, up to date on everything going on with our portfolio.

It seems like every year it gets crazier and crazier. And I relish this time where I can just step back and think about what’s really important and what brings us all together as a human community.

Communal Commonalities

There are two things in life that every person on earth will experience: birth and death.

The second is something we all hate to talk or even think about and are doing everything we can do to push off.

In the United States, 75% of deaths can be attributed to the top 10 causes. And the top three — heart disease, cancer, and chronic lower respiratory disease — lead to 50% of all deaths.

When it comes to heart disease, there are lots of things we can do to prevent it:

  • Follow instructions to ensure safe use of medications and any OTC drugs
  • Eat a diet that is low in salt, refined sugars, total fat, saturated fat, and cholesterol and high in fresh fruits and vegetables
  • Exercise regularly (at least 150 minutes a week)
  • Avoid excessive intake of alcohol
  • Quit smoking
  • Take steps to reduce stress levels, or get help with stress management

But with the number two killer, cancer, there isn’t a lot. Anyone can develop cancer. Even those with the healthiest lifestyles are still at risk of this disease that accounts for 22.5% of deaths in the U.S.

And up until just recently, there haven’t been many options for treating cancer. Surgical removal of tumors is one, but that only works if the cancer is caught early and is localized in one or two places. Once it metastasizes and spreads to multiple organ systems, the only options are radiation and chemotherapy.

They’re moderately effective and have improved the chances of surviving this killer. But they’re both also devastating to the healthy cells in a person’s body.

A Global Epidemic

According to the World Health Organization, 8.8 million people worldwide died from cancer in 2015. That’s nearly one of every six global deaths. It also estimates that in 2010, the global cost of cancer was $1.16 trillion — with a “T.”

And according to the National Cancer Institute in the U.S., nearly 40% of men and women will be diagnosed with cancer in their lives. That’s nearly 2 trillion people — again, that’s trillion with a “T.” And that’s just using the current global population. That number grows literally every second.

Right now, we can expect 26% of the world to be diagnosed with cancer at some point in their adult lives. And all those kids who make up the other 35% of the population, well, once they’re adults, we can expect 40% of them to be diagnosed, too.

As more and more people are diagnosed, that $1.16 trillion hospital bill is only going to get bigger.

Chemicals and Cash

Up until now, chemotherapy has been the most successful treatment. And it’s become a multibillion-dollar industry. In 2013, the top 10 chemo drugs brought in nearly $40 billion in sales for their patent owners. The top three combined brought in over 50% of that.

In 2013, Biogen was raking in $7.78 billion a year from its chemo drug Rituximab. And Roche saw revenues of $13.31 billion from its two drugs, Bevacizumab and Trastuzumab.

Roche has tripled in value since 2003. Its subsidiary that’s responsible for these breakthrough drugs, Genentech, had a stock price of $1 in 2012. By May of last year, it had peaked at $55.20. That’s a 5,157% gain in just four years. And it's all thanks to owning the patents to two of the top chemo drugs on the market.

Biogen chemists developed Rituximab back in the 1990s and patented it in 1998. That patent ran out two years back in 2015. But between 1998 and 2015, Biogen was raking in big-time money from its top-selling cancer treatment. And Biogen shareholders were raking in some big-time profits of their own.

biogen gains

From the time the medicine was patented and started being used to the time the patent ran out, Biogen stock soared a whopping 13,553%! That’s enough to turn a modest $10,000 investment into over $1.36 million!

Just imagine if you could have known how successful this drug would be. And imagine you knew and invested in Biogen before anyone else in the investing world caught wind of how earth shattering this new cancer treatment would become.

Now, like I said, chemotherapy is very successful in the treatment of cancer. And it’s dropped cancer’s mortality rate drastically. But it’s still a terrible process. Hair falls out. Toenails and fingernails fall off. Patients feel nauseous. They lose energy. They basically feel like they’re dying. Because that’s what chemo does to your body’s cells: It kills them. The hope is that it can be targeted to kill more cancer cells than healthy ones. And while it works, it’s not an experience anyone would wish to undergo.

But there’s hope. Not so much that we can stop cancer the way we did smallpox and polio. But that we can cure it once it strikes. And that we can do it without damaging so many healthy cells like we currently do with chemo and radiation.

The Future of Medicine

The company at the forefront of this groundbreaking technology is going to become the next Roche and Genentech, or the next Biogen.

It’s a single shot that targets only the cancerous cells. Unlike chemo, patients don’t have to go in monthly or weekly for ongoing treatments. And they also don’t get chemical poisons pumped into their bodies.

And not only is it much friendlier on patients than chemo or radiation, but it actually works!

In lab testing to date, a stunning 94% of those suffering from an acute form of leukemia went into full remission after receiving the treatment, and this was after all other treatments had failed!

It’s so revolutionary that a major biotech firm in California recently paid $11.9 billion for access to this disruptive medical technology.

And oncology experts all over the world are singing its praises…

“The whole cancer world is going to be changed forever,” says Dr. Carl June of the University of Pennsylvania medical school.

“This, to me, is the most promising therapy I’ve seen in my career, period,” says Dr. Henry Friedman of the Duke University School of Medicine.

Even the FDA is calling this treatment “historic.”

And one small company holds the key — not only to this earth-shattering cancer treatment, but also to unlocking a fortune in profits as it cures the cancers of the world.

My colleague, Charles Mizrahi, was one of the first analysts to pick up on the phenomenal potential of this little-known company. And he’s put together a presentation just for Wealth Daily members.

He’s not sharing this information with anyone else. But he and I want you to know exactly what’s going on with what’s been called a “transformative” therapy from “one of the more potentially transformative and disruptive companies [JPMorgan has] come across.”

This revolutionary therapy is going to change the future of global medicine. It could literally go down as the biggest medical breakthrough of the 21st century.

And this company could change the lives of anyone bold enough and smart enough to invest in it before the rest of Wall Street finds out about its potential.

I insist you hear what Charles has to say. It’s an opportunity you don’t want to miss and I don’t want you to miss out on. If you prefer to read more about it, you can click here for a written report on the treatment and the company that’s going to mint a new generation of medical millionaires.

I hope you’ll take a few minutes of your time to check this out. You won’t be disappointed.

To your wealth,

Jason Williams
Wealth Daily

Follow me on Twitter @AllBeingsEqual

Comments

Buffett's Envy: 50% Annual Returns, Guaranteed